Back to Search
Start Over
Tau phosphorylation by glycogen synthase kinase 3β modulates enzyme acetylcholinesterase expression
- Source :
- Digital.CSIC: Repositorio Institucional del CSIC, Consejo Superior de Investigaciones Científicas (CSIC), Journal of Neurochemistry, Digital.CSIC. Repositorio Institucional del CSIC, instname
- Publication Year :
- 2022
- Publisher :
- Blackwell Publishing Inc, 2022.
-
Abstract
- Early View: Online Version of Record before inclusion in an issue.<br />In Alzheimer's disease (AD), the enzyme acetylcholinesterase (AChE) co‐localizes with hyperphosphorylated tau (P‐tau) within neurofibrillary tangles. Having demonstrated that AChE expression is increased in the transgenic mouse model of tau Tg‐VLW, here we examined whether modulating phosphorylated tau levels by over‐expressing wild‐type human tau and glycogen synthase kinase‐3β (GSK3β) influences AChE expression. In SH‐SY5Y neuroblastoma cells expressing higher levels of P‐tau, AChE activity and protein increased by (20% ± 2%) and (440% ± 150%), respectively. Western blots and qPCR assays showed that this increment mostly corresponded to the cholinergic ACHE‐T variant, for which the protein and transcript levels increased ~60% and ~23%, respectively. Moreover, in SH‐SY5Y cells differentiated into neurons by exposure to retinoic acid (10 µM), over‐expression of GSK3β and tau provokes an imbalance in cholinergic activity with a decrease in the neurotransmitter acetylcholine in the cell (45 ± 10%). Finally, we obtained cerebrospinal fluid (CSF) from AD patients enrolled on a clinical trial of tideglusib, an irreversible GSK3β inhibitor. In CSF of patients that received a placebo, there was an increase in AChE activity (35 ± 16%) respect to basal levels, probably because of their treatment with AChE inhibitors. However, this increase was not observed in tideglusib‐treated patients. Moreover, CSF levels of P‐tau at the beginning measured by commercially ELISA kits correlated with AChE activity. In conclusion, this study shows that P‐tau can modulate AChE expression and it suggests that AChE may possibly increase in the initial phases of AD.<br />MACG is supported by a GVA-Predoctoral fellowship from Generalitat Valenciana, Spain. This study was funded by Instituto de Salud Carlos III (ISCIII), Fondo de Investigaciones Sanitaria (grants CP11/00067 and PI17/00261 to MSGA); co-financed by Fondo Europeo de Desarrollo Regional and through CIBERNED, ISCIII, Spain.
- Subjects :
- 0301 basic medicine
Male
Glycogen synthase kinase-3β
Xenopus
Retinoic acid
Biochemistry
chemistry.chemical_compound
Mice
0302 clinical medicine
GSK-3
Pregnancy
Cricetinae
Phosphorylation
Neurotransmitter
Cells, Cultured
Aged, 80 and over
Molecular Basis of Disease
Mice, Inbred ICR
biology
tau phosphorylation
glycogen synthase kinase‐3β inhibitor
acetylcholinesterase
glycogen synthase kinase‐3β
Middle Aged
Alzheimer's disease
Acetylcholinesterase
Cerebrospinal fluid
language
Original Article
Female
Acetylcholine
medicine.drug
medicine.medical_specialty
Aché
tau Proteins
Tau phosphorylation
CHO Cells
cerebrospinal fluid
Gene Expression Regulation, Enzymologic
03 medical and health sciences
Cellular and Molecular Neuroscience
Cricetulus
Alzheimer Disease
Internal medicine
Cell Line, Tumor
medicine
Animals
Humans
Glycogen synthase kinase-3β inhibitor
Glycogen synthase
Aged
Glycogen Synthase Kinase 3 beta
language.human_language
030104 developmental biology
Endocrinology
chemistry
biology.protein
Cholinergic
ORIGINAL ARTICLES
030217 neurology & neurosurgery
Biomarkers
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Digital.CSIC: Repositorio Institucional del CSIC, Consejo Superior de Investigaciones Científicas (CSIC), Journal of Neurochemistry, Digital.CSIC. Repositorio Institucional del CSIC, instname
- Accession number :
- edsair.doi.dedup.....cfb157439a0b15028f23d735758c4a53